News

Impilo believes in transparency. We know that our operations arouse curiosity and we understand the importance of maintaining an open relationship with the outside world. Accordingly, we present information about our operations and our investments in order to increase transparency. 

Manufacturing I (1) (1)

Impilo divests leading haemostatic device developer and manufacturer Ferrosan Medical Devices to Danish consortium of long-term investors

Impilo divests leading haemostatic device developer and manufacturer Ferrosan Medical Devices to Danish consortium of long-term investors
Microscope is used for conducting planned, research experiments, educational demonstrations in medical and health institutions, lab.

Scantox acquires Timeline Bioresearch and Adlego Biomedical – strengthening its position as the leading Nordic provider of pre-clinical research services

Scantox A/S, the leading Nordic GLP-compliant pre-clinical contract research organization, headquartered in Denmark and since 2021 owned by Impilo, is pleased to announce the acquisitions of Swedish Timeline Bioresearch AB in Lund and Adlego Biomedical AB in Stockholm. Timeline Bioresearch and Adlego Biomedical possess leading capabilities in efficacy and explorative research services and bring highly complementary service offerings to Scantox’s stronghold in pharmacology and regulatory toxicology. Moreover, the acquisitions represent important first steps towards broadening the Company’s portfolio of services, to support its growing customer base earlier in the drug development process.
Businessman on blurred background using modern molecule structure 3D rendering

Actinium Pharmaceuticals and Immedica Announce Commercialization Agreement for Iomab-B

Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa
Impilo ESG Report picture

Sustainability Report for 2021

During 2021, we have taken important steps to create more value from our sustainability efforts by better articulating the health impact of our investment approach.
Sunflowers

We Stand With Ukraine

We are deeply saddened and concerned by the events unfolding in Ukraine and we would like to express our deepest solidarity with all of those who are affected by it.
image001 (1)

Impilo has completed the acquisition of tandlægen.dk – Denmark’s leading dental chain

Impilo has completed the acquisition of tandlægen.dk, Denmark's leading dental chain with more than 50 clinics, that provide high-quality dental...
mallax-pic

Mallax acquires Sana Pharma Medical and creates a new Nordic

Mallax Pharmaceuticals AB (”Mallax”) has acquired Sana Pharma Medical AS (”SPM” or the “Company”) and creates a new Nordic...
corporate-social-responsibility-1200x800

Impilo’s divestment of NutraQ to Orkla completed

On 15 June 2021, the sale of NutraQ to Orkla Health was completed after approval from all relevant competition authorities. NutraQ is a leading...

Media

We know that our operations arouse curiosity and we understand the importance of maintaining an open relationship with the outside world. Here you will find press information, news and media material.

Redefining know-how

Impilo is zulu and xhosa meaning life, health or simply the meaning of a healthy life. We chose this name to highlight our sector-focus and our ambition to provide know-how and new perspectives to Nordic healthcare companies.

If you would like to receive a notification via e-mail when we publish a news update please submit your e-mail adress below.